Mass General Home

Growth Hormone
 

Effects of Growth Hormone Administration on Cardiovascular Risk Markers in Men and Women with Cured Acromegaly

This 12-month research study will evaluate the relationship between growth hormone (GH) levels and heart disease in subjects cured of acromegaly. GH is a hormone that the pituitary gland normally produces, and GH deficiency is associated with an increased risk for heart disease. This study investigates whether physiologic GH replacement therapy will reduce cardiovascular risk in men and women ages 18 to 75 with GH deficiency following cure of acromegaly. Eligible subjects may undergo 8 to 10 outpatient hospital visits which will include measurements of metabolism, body fat and muscle, as well blood tests reflecting the health of blood vessels. Subjects will be remunerated up to $300 for their participation.

We will also enroll subjects cured from acromegaly who are GH sufficient or who are GH deficient but have a contraindication to receiving GH for a cross-sectional study involving body composition and cardiovascular risk marker measurements.

 

For more information, please contact Lindsay Gunnell at (617) 724-1579 or lgunnell@partners.org

 

Growth Hormone, Cardiovascular Risk, and Visceral Adiposity in Women

Are you an overweight woman? We are conducting a research study at the Massachusetts General Hospital to determine whether a treatment can decrease body fat and reduce the risk of heart disease. You may be eligible if you are between 18 and 45 years old; have regular menstrual periods; and do not take medicines for weight loss, cholesterol, blood sugar, or birth control. The study includes nine visits over twelve months with compensation up to $600.
 
For more information, please contact Dr. Andrea Utz at (617) 726-1428

 

For additional educational information and resources on pituitary disorders, please see the Educational Information section of this site.